# Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment

> **NCT02055118** · PHASE2,PHASE3 · COMPLETED · sponsor: **Shire** · enrollment: 58 (actual)

## Conditions studied

- Hunter Syndrome

## Interventions

- **BIOLOGICAL:** idursulfase-IT
- **OTHER:** No IT treatment

## Key facts

- **NCT ID:** NCT02055118
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-24
- **Primary completion:** 2017-09-28
- **Final completion:** 2017-09-28
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2021-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02055118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02055118, "Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02055118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*